Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Affiliations

• ¹ Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, NC. rmesa@wakehealth.edu.
• ² The University of Texas MD Anderson Cancer Center, Houston, TX.
• ³ Leipzig University Hospital, Leipzig.
• ⁴ Princess Margaret Cancer Centre, Toronto, Ontario.
• ⁵ Hadassah-Hebrew University Medical Center, Jerusalem.
• ⁶ Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza.
• ⁷ Institut Universitaire du Cancer de Toulouse, Université de Toulouse III, Toulouse.
• ⁸ Université Paris Cité, AP-HP, Ho_pital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC1427, Paris.
• ⁹ Washington University School of Medicine, St. Louis, MO.
• ¹⁰ Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
• ¹¹ Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.
• ¹² University of Insubria, Varese.
• ¹³ University of Florence and AOU Careggi, Florence.
• ¹⁴ Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary.
• ¹⁵ Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
• ¹⁶ Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland.
• ¹⁷ Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
• ¹⁸ University of Miyazaki, Miyazaki, Japan.
• ¹⁹ Guy's and St Thomas' NHS Foundation Trust, London.
• ²⁰ Sierra Oncology, Inc., San Mateo, CA.